Table 1.
WT1 related malignant diseases.
| Malignant diseases | Study model | Mechanism | Refs |
|---|---|---|---|
| AML | AML patients; K562 cells; MLL-AF9-induced murine; Wt1fl/+ mice; THP1 cell; Highly enriched human CD34+ cell |
Active BCL2/CCNA1; ↓MYC,CND1; WT1-MEG3 axis abnormal; WT1 with FIT3-ITD; WT1heterozygosity/haploinsufficiency |
13–19 |
| MDS | MDS patients; Mice model; | WT overexpression; WT1(R394 W) and FLT3/ITD mutation |
23–24 |
| T-ALL | T-ALL patients; MOLT4, PF382 and CCRF-HSB2 cells; | ↑IL7R-JAK-STAT; NOTCH1/FBXW7/FLT3 mutation |
26–29 |
| CML | CML patients; K562 cell; JURL-MK1\CD34+ cells | ↑WT1; Active BCR/ABL1,PI3K/Akt, ZNF224, Wt1/ZNF224/c-Myc |
31–33 |
| APL | APL patients | Non-coding mutation in the WT1 intron; MYB disruption |
36 |
| Lung Cancer | NSCLC patients; H1568/ H1650 NSCLC cell line; Wt1Lox/Lox mice |
↓CDH1;WT1-AS,PI3K/AKT; ↑Srpk1, Srsf1, VEGF isoforms |
40,41 |
| Breast cancer | BC patients; MDA-MB-231 cell | WT1 hypermethylation; ↑IGF 1R, IGF II, ↑EphA2, β-catenin |
46–48 |
| Neuroblastoma | NB69 cell; NB tissue; SH-SY5Y cell | ↑WT1 isoforms; Inhibite PI3K/Akt and MAPK/ERK pathways; |
51,52 |
| Prostate cancer | PCa/ PC3/DU145/LNCaP cell; | ↑WT1, VEGF, SRPK1; ↓E-calmodulin |
56–58 |
| Hepatocellular carcinoma |
MHCC97 L cell; Huh7, HLE, Huh7.5.1 cell |
↑WT1, LEF1, β-catenin, Wnt/ JAK2/STAT3 and MAPK signaling; Regulate cFLIP, FADD, and NF-κB |
66–67 |
| Pancreatic ductal adenocarcinoma | PC patients; AsPC-1/BxPC-3/PANC-1/MIA PaCa-2/ SW1990 cell lines; PANC-1/Capan-1/HDPE6C7 cell line |
Modulate miR-216a/KRT7 axis, USP5-E-calmodulin axis; ↑PI3K/AKT, STAT3 |
70,71 |
| Ovarian Cancer | OC patients; IOSE386/ A2780/HO8910//HO8910PM cell lines; HOSEpiC/IOSE80 cells | ↑ERK1/2; ↓E- calmodulin; Rap1/ Ras/MAPK signaling pathways |
76,77 |
| Astrocytomas | Astrocytomas patients; T98G/ LN18/ LNZ308/LN229 /U87MG/ VC95 G cell lines |
↑WT1; ↓IGF-1R | 81,82 |
| Malignant pleural mesothelioma | MPM patients | WT1 regulates MET and EMT | 87,88 |